Fig. 3
From: Clustering of HR + /HER2− breast cancer in an Asian cohort is driven by immune phenotypes
Comparison of characteristics between HR + /HER2− Group 1 and Group 2. a Somatic driver mutations in Group 1 and Group 2. b Mutational signatures of Group 1 and Group 2. c Number of somatic mutations in Group 1 and Group 2. d Comparison of homologous recombination deficiency (HRD) scores between Group 1 and Group 2. LOH = loss of heterozygosity, LST = large-scale state transitions, TAI = telomeric allelic imbalance. A significance level of p = 0.05 was used